Hey There
We’re here to help you make sense of that alphabet soup called DNA, so you don’t need a PhD to take charge of your health.
Think of us as your friendly genetic navigator: guiding you through the twists and turns of your genes so you can make smarter choices, feel better, and maybe sleep a little easier at night, without Googling symptoms at 2 a.m.
Live better, stress less.
Our Team
Our founders like to joke that we’ve been around the block - Let’s just say we’re not your typical startup founders fresh out of graduate schools. We were decoding DNA when flip phones were cool and sequencing a single gene took a small miracle (and a budget the size of a small country’s GDP).
With decades of late nights and scientific breakthrough "aha!" moments, we’ve dedicated our careers to unraveling the human genome and making personalized medicine more than just a buzzword.
That passion is the spark behind Nova - a company fueled by expertise, scientific integrity, and an obsession with making advanced genetic insights accessible to everyone.
Management
_JPG.jpg)
Daniel C. Siu, M.S., MBA
Founder & CEO Daniel is the founder and CEO of Nova. With over 35 years of experience in genetics and the life sciences, he has spent his career helping make complex DNA science more useful and easier to understand, for doctors, everyday patients and families. Before starting Nova, Daniel helped launch several companies focused on genetic testing and DNA technologies. One of them, Rainbow Genomics, was founded in 2016, which brought clinical whole genome sequencing to children and adults across Asia - a technology just beginning to be a common clinical practice in the US. Prior to that, he was VP of sales & marketing at Nextcode Health, a gene software platform company spun out from deCODE Genetics, which was acquired within its first year. He also co-founded a company called Axeq Technologies, which later joined with Macrogen to become one of the largest DNA sequencing service providers in the world. Earlier in his career, Mr. Siu held key roles at several science and biotech companies, including Beckman Instruments, deCODE Genetics, and Applied Biosystems. At Beckman, he helped launch the P/ACE system in 1990 - the first machine that could automatically analyze DNA. Later on, he worked on software for the ABI 3700 Genetic Analyzer, which played a key role in helping scientists complete the mapping of the human genome. From 2005 to 2011, he took the reins as Managing Director at deCODE Genetics, where he helped take their genetic research services global. He studied molecular biology, earning a BS degree from the University of Texas at Austin, followed by a master’s degree in chemistry from the University of Minnesota, and later completed his MBA at San Francisco State University. With Nova, Daniel hopes to make high-quality genetic testing more accessible, more affordable, and more meaningful, so more people can take control of their health with confidence and clarity.
Contributors
Maggie Law, FHGSA., MMedSc., MGenCouns
Board-Certified Genetic Counselor (Pro Bono) Ms. Maggie Law, a board-certified genetic counselor, has joined Nova offering her clinical expertise to help ensure that our genetic insights are not only accurate, but also ethical, clear, culturally sensitive, and meaningful to patients and families. Maggie brings over a decade of experience in variant interpretation and genetic counseling for individuals and families from diverse ethnic and cultural backgrounds. She is skilled at interpreting complex or ambiguous genetic findings in underrepresented populations, and in navigating the language, cultural, and health literacy needs of patients from across international communities. At Nova, Maggie collaborates with our AI team to ensure that hard-to-understand genetic insights, such as polygenic risk scores, inherited cancer predispositions, and carrier status, are translated into clear, actionable information. She helps in producing multilingual, culturally sensitive summaries that are medically accurate yet easy to understand, inclusive, and relatable for real-world use across different communities. Maggie also ensures that AI is used in an ethical way. Maggie currently practices as a licensed genetic counselor at the Hong Kong Sanatorium & Hospital, and at the cancer genetics services under the Hong Kong Hospital Authority. Her dual roles in both private and public healthcare settings reflect her commitment to advancing patient-centered genetic care across health systems.
Clinical Advisory Board
Jeffrey Gulcher, M.D., Ph.D.
Executive Advisor. Clinical Affairs and Global Alliances Jeff has spent his career at the forefront of genetics and medicine. He co-founded deCODE genetics in 1996, a groundbreaking company that was one of the first to study DNA across an entire country. deCODE helped scientists around the world understand how genes influence health and diseases at a population level. After deCODE was acquired by Amgen in 2012, Jeff helped launch several other genetics-focused companies, including NextCODE Health, WuXi-NextCODE, Genomics Medicine Ireland, and Genuity Science. He has authored over 200 scientific papers on the role of genes in diseases such as diabetes, heart disease, and neurological disorders. Today, as the chief medical officer & senior vice president at Galatea Bio, he continues to guide clinical and global efforts to make advanced genetic science more meaningful and accessible for patients everywhere. Jeff earned both his M.D. and Ph.D. from the University of Chicago, and completed his neurology training at Harvard Medical School hospitals.